摘要
随着新一代基因测序技术以及癌生物学的迅猛发展,基于基因组生物标志物的抗肿瘤精准药物开发成为药物研发的重要方向。介绍了抗肿瘤精准药物在非小细胞肺癌、乳腺癌、黑色素瘤以及白血病等肿瘤领域表现出的优异治疗效果,剖析了目前已上市以及处于研发阶段的“泛癌种”药物,表明基于生物标志物而非肿瘤组织的治疗药物将成为抗肿瘤药物研发的方向之一。介绍了以“篮子试验”和“雨伞试验”为代表的抗肿瘤药物新型临床试验设计以及PROTACs药物开发新技术,指出新理念新技术的出现将进一步推动抗肿瘤精准药物发展,促进针对耐药或“不可成药靶点”的靶向药物的开发。
With the rapid development of the next generation sequencing(NGS)technology and cancer biology,genomic biomarker-based personalized anti-cancer medicines have become an important direction of drug discovery.In this review,we first briefly introduce the excellent therapeutic effects of personalized anti-tumor medicines on non-small cell lung cancer,breast cancer,melanoma and leukemia.Next,we comprehensively explore current tumor agnostic anticancer medicines and highlight that therapeutic medicines based on biomarkers rather than tumor tissue will become one of the directions of antitumor drug discovery.Finally,after introducing the novel clinical trial design and the new technology of PROTACs,we argue that the emergence of new ideas and new technologies will promote the development of antitumor precision medicines and help solve the problem of drug-resistance and"undruggable"targets.
作者
黄瑶庆
王春丽
李子艳
毛艳艳
刘丽丽
HUANG Yaoqing;WANG Chunli;LI Ziyan;MAO Yanyan;LIU Lili(Information Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China)
出处
《科技导报》
CAS
CSCD
北大核心
2022年第13期86-95,共10页
Science & Technology Review
基金
上海市科委“科技创新行动计划”软科学基金项目(21692191100)。
